Marché du diagnostic du cancer du sein en Amérique du Nord – Tendances et prévisions du secteur jusqu’en 2030

Analyse et perspectives du marché du diagnostic du cancer du sein en Amérique du Nord

Le cancer du sein est la maladie la plus courante dans la population, survenant principalement chez les femmes atteintes de maladies prolifératives. Le cancer du sein se développe principalement dans les tissus mammaires. Les symptômes du cancer du sein comprennent des bosses dans le sein, une différence de taille et de forme des seins, un écoulement des mamelons et des plaques rouges irritées et squameuses sur la peau. L'incidence du cancer du sein chez les femmes augmente à chaque fois que la croissance du marché du cancer du sein augmente avec la croissance des médicaments. Méthodes avancées de diagnostic du cancer du sein avec des techniques développées. Amélioration des technologies développées dans le cancer du sein en augmentant l'efficacité, la précision, l'efficience, la fiabilité et la rapidité des résultats et en améliorant la détection des troubles. Fonctionnalités avancées pour détecter le cancer en moins de temps. Le cancer est détecté à un stade précoce, ce qui aide les patients à récupérer plus rapidement, empêche les cellules cancéreuses de se propager à d'autres parties du corps et les traite avec de nouveaux médicaments sur le marché. L'augmentation du dépistage et de l'imagerie des tumeurs stimulera le marché du cancer du sein. Cela élargit le marché du cancer du sein avec un nombre croissant de patients chaque année, et le taux de guérison du cancer du sein augmente. Soutien gouvernemental en augmentant la disponibilité de nouveaux projets de développement de médicaments et en augmentant l’efficacité et l’efficience du traitement et l’intégration de nouveaux médicaments dans le domaine médical.

Cependant, le coût élevé des traitements de diagnostic du cancer et le manque de professionnels qualifiés sont les facteurs qui freinent la croissance du marché.

Data Bridge Market Research analyse que le marché nord-américain du diagnostic du cancer du sein devrait atteindre la valeur de 3 898,38 millions USD d'ici 2030, à un TCAC de 9,5 % au cours de la période de prévision. Le type de test représente le segment de type de diagnostic le plus important du marché en raison de l'augmentation du nombre de patientes atteintes du cancer du sein et des avancées technologiques dans le traitement du cancer du sein en Amérique du Nord. Ce rapport de marché couvre également en profondeur l'analyse des prix, l'analyse des brevets et les avancées technologiques.

North America Breast Cancer Diagnostics Market Definition

Breast cancer is a disease in which the uncontrolled growth of malignant cells in the breast tissue occurs more often in women than in men. Breast cancer is the uncontrolled cell division of breast cells, which are the most common cells in the mammary glands and ducts. Some symptoms of breast cancer include a lump or lump in the breast, bloody discharge from the nipple and a change in the shape of the nipple or breast. Breast cancer treatment depends on the stage of cancer. Its treatment consists of chemotherapy, radiation therapy, hormone therapy, and surgery.

Breast cancer is another type of cancer that is more common in women than in men. A number of the symptoms of the sickness hold bleeding secretion from the reproductive organ, a lump or block within the breast, and variations in the texture or form of the breast or nipple. Breast cancer treatment depends on the stage of cancer. In addition, its treatment includes radiotherapy, therapy, hormone therapy and surgery. Early detection of carcinoma is essential for the effective treatment of the disease. Early detection of the disease also leads to better outcomes, including many treatment options, better survival and better quality of life. Increasing pressure and demand for new forms of treatment or methods of treatment are due to the rapidly increasing spread of diseases.

North America Breast Cancer Diagnostics Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:    

Drivers

• Launch of technologically advanced diagnosis & therapeutics to aid growth

Breast cancer is the most common disease in the population, occurring mainly in women with proliferative disease. Breast cancer develops in the breast tissues. Symptoms of breast cancer include lumps in the breast, differences in the size and shape of the breast, discharge from the nipples, and itchy, scaly red patches on the skin. This disease spreads in body with increasing symptoms such as bone pain, swollen lymph nodes, difficulty in breathing and many others. Increasing research and development with new technologies and treatments developed for breast cancer will significantly contribute to market growth.

Moreover, Technological advances in imaging are creating new opportunities for improvements in both screening and early detection. One technology advance is 3-D mammography, also called breast tomosynthesis. This procedure takes images from different angles around the breast and builds them into a 3-D-like image.

In the recent times, several advancements in technology is changing the fate of cancer diagnostics, as mentioned above some of the recent advancements, several other technologies are currently under trial phase which are on the limit of changing the process of breast cancer diagnostics. These technological advancements in the field are acting as a major drivers for North America breast cancer diagnostics market.

• Increasing prevalence of breast cancer

One of the major factors driving the growth of the North America market is the increasing prevalence of breast cancer worldwide, which is expected to lead to a large number of patients in need of accurate and effective treatment options. Breast cancer is one of the most common cancers in the world, and better diagnostics are expected to increase the number of patients diagnosed in the future.

In addition, the growing demand for preventive care and early treatment has led to many cancer screenings, which would also increase the number of patients with a high need for treatment during the forecast period.

Thus, increasing prevalence of breast cancer leads to more diagnosis of cases and hence it is expected to drive the market growth during the forecast period.

Restraint

• Adverse effects of breast cancer therapeutics

Screening is looking for cancer before a person has any symptoms. This can help find cancer at an early stage. When abnormal tissue or cancer is found early, it may be easier to treat. By the time symptoms appear, cancer may have begun to spread. Several screening tests are used for detecting breast cancers which include breast magnetic resonance imaging, diagnostic mammogram, biopsy etc. Although these test are considered to be standard for diagnosing breast cancer, they have their associated risks which include false-negative results, false-positive results, and side effects such as undue psychological stress, excessive radiation exposure, and a serious risk of tumor rupture and spread of cancerous cells.

Opportunity

• Initiatives taken by the government

Government is focusing on increasing the initiative for breast cancer treatments with advanced techniques to improve the health of patients. Providing he number of insurances, such as benefits, has been increased so that ordinary people can choose treatment and take advantage of available medicines and treatments to improve their quality of life. In developing countries such as China and India, the government has launched several programs and initiatives to raise awareness about the disease. This has greatly increased the demand for breast cancer diagnosis and disease management therapies. Increasing mergers and acquisitions between pharmaceutical companies and government agencies are among the main trends in the North America breast cancer market.

Rates of new breast cancer cases have risen 0.6% per year from 2010-2019, and death rates have risen an average of 1.7% per year for the same time frame. As the breast cancer patient rate is increasing, the use of treatments and advanced technologies for the diagnosis of cancer will increase, which is an opportunity for market growth.

Challenge

• Lack of diagnostic infrastructure

Non-communicable diseases such as breast cancer and other types of cancer have now been recognized by the United Nations and WHO as a major public health crisis. Cancer is the biggest part of this problem, and health systems face a major challenge to improve cancer care, control costs and increase system efficiency. Differences in treatment approach and outcomes between high income countries and low and middle income countries are striking. Reasons for this disparity include cost, access to care, workforce and training gaps, and lack of awareness among the lay and medical community.

Moreover, compared to early diagnosis, cancer screening is a separate and more complex public health strategy that requires additional resources, infrastructure and coordination. Rural, developing and low income countries in the different regions does not have enough infrastructure to maintain with the new kits and fro the sample storage as well. These countries need diagnostic infrastructure to ensure the early detection and rapid, accurate diagnosis of the disease.

Post-COVID-19 Impact on North America Breast Cancer Diagnostics Market

The COVID-19 pandemic has caused disruptions in elective health services related to breast screening, pre-cancer care and management of abnormal screening results. This could lead to an increase in the incidence of breast cancer, exacerbating existing health inequalities.

Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities and product launch and strategic partnerships to improve the technology and test results involved in the market.

Recent Developments

• In November 2022, Koninklijke Philips N.V., announced the North America launch of a next-generation compact portable ultrasound solution at the Radiological Society of North America (RSNA) annual meeting to bring the diagnostic quality associated with premium cart-based ultrasound systems to more patients. It is portable and versatile with good image quality or performance. It is Compatible with Philips ultrasound systems Affiniti and EPIQ transducer. This has helped company to expand its product portfolio.
• In November 2022, Siemens Healthineers and Atrium Health, a leading not-for-profit healthcare provider known for leading pediatric, cancer and cardiac care programs, have announced a multi-year value partnership1. This strategic agreement focuses on improving access to care in Atrium Health's service area in the southeastern United States, improving health equity and increasing economic mobility. Atrium Health is acquiring more than $140 million in equipment and devices from Siemens Healthineers, including advanced imaging technology, radiation oncology and precision endovascular robotics. This has helped the company to expand their business.

North America Breast Cancer Diagnostics Market Scope

North America breast cancer diagnostics market is segmented into test type, type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE

• IMAGING
• BIOPSY
• GENOMIC TEST
• BLOOD TEST
• OTHERS

On the basis of test type, the North America breast cancer diagnostic market is segmented into imaging, biopsy, genomic test, blood tests and others.

NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE

• DUCTAL CARCINOMA IN SITU
• INVASIVE DUCTAL CARCINOMA
• INFLAMMATORY BREAST CANCER
• METASTATIC BREAST CANCER

On the basis of type, the North America breast cancer diagnostic market is segmented into ductal in situ carcinoma, invasive ductal carcinoma, inflammatory breast cancer, and metastatic breast cancer.

NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY END USER

• HOSPITALS
• CLINICS
• RESEARCH & ACADEMIC INSTITUTES
• DIAGNOSTIC CENTERS
• OTHERS

On the basis of end user, the North America breast cancer diagnostic market is segmented into hospitals, clinics, research and academic institutes, diagnostic centers and others.

NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL

• DIRECT TENDER
• RETAIL SALES
• OTHERS

On the basis of distribution channel, the North America breast cancer diagnostic market is segmented into direct tender, retail sales and others.

North America Breast Cancer Diagnostics Market Regional Analysis/Insights

The North America breast cancer diagnostics market is analyzed and market size information is provided test type, type, end user, and distribution channel.

The countries covered in this market report U.S., Canada and Mexico.

En 2023, les États-Unis dominent l’Amérique du Nord en raison de la présence d’acteurs clés du marché sur le plus grand marché de consommation avec un PIB élevé et en raison de sa dernière technologie avancée de diagnostic du cancer et de ses inventions dans le diagnostic du cancer du sein.

La section du rapport sur les pays fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que les nouvelles ventes, les ventes de remplacement, la démographie des pays, les actes réglementaires et les tarifs d'importation et d'exportation sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques nord-américaines et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, ainsi que l'impact des canaux de vente sont pris en compte lors de l'analyse prévisionnelle des données nationales.

Analyse du paysage concurrentiel et des parts de marché du diagnostic du cancer du sein en Amérique du Nord

Le paysage concurrentiel du marché nord-américain du diagnostic du cancer du sein fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements en R&D, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement de produits, les pipelines d'essais de produits, les approbations de produits, les brevets, la largeur et l'ampleur du produit, la domination des applications, la courbe de survie technologique. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise vers le marché nord-américain du diagnostic du cancer du sein.

Certains des principaux acteurs opérant sur le marché du diagnostic du cancer du sein en Amérique du Nord sont F-Hoffmann La Roche Ltd., Siemens Healthcare GmbH, General Electric, Koninklijke Philips NV, FUJIFILM Corporation, Abbott, Hologic, Inc., OncoStem, Provista Diagnostics, Thermo Fisher Scientific Inc., Myriad Genetics, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., BD, NanoString., Cepheid, BIOMÉRIEUX, Exact Sciences Corporation, Biocept, Inc. et Abacus ALS.

SKU-69764